<DOC>
	<DOCNO>NCT02123576</DOCNO>
	<brief_summary>Pentoxyfylline therapy addition standard care albumin , midodrine octreotide therapy superior standard care alone treatment Type I hepatorenal syndrome first 14 day hospitalization .</brief_summary>
	<brief_title>Treatment Type I Hepatorenal Syndrome ( HRS ) With Pentoxyfylline</brief_title>
	<detailed_description>Each hospitalize subject undergo pre-dosing screen review history physical exam day enrollment safety assessment ensure contraindication use PTX . Type I HRS define accord criterion put forth American Association Study Liver Disease ( 1 ) cirrhosis ascites ; ( 2 ) serum creatinine great 1.5 mg/dL ; ( 3 ) improvement serum creatinine ( decrease level 1.5 mg/dL less ) least two day diuretic withdrawal volume expansion albumin ; ( 4 ) absence shock ; ( 5 ) current recent treatment nephrotoxic drug ; ( 6 ) absence parenchymal kidney disease indicate proteinuria &gt; 500 mg/day , microhematuria ( &gt; 50 red blood cell per high power field ) , and/or abnormal renal ultrasonography . Baseline test obtain hospitalization record , include limited chemistry panel , liver function testing , urinalysis , urine electrolyte , coagulation study , blood culture , chest x-ray , diagnostic paracentesis , abdominal ultrasound Doppler . Subjects take either placebo three time day pentoxyfylline 400mg three time day 400mg twice day eGFR 10-50 400mg day eGFR &lt; 10 90 day addition standard AMO therapy . Treatment continue 14 day unless study endpoint reach time either PTX placebo stop</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Hospitalized patient acute chronic liver disease Type I HRS Aged great equal 18 Nonpregnant Allergy hypersensitivity PTX intolerance methylxanthines ( e.g . caffeine , theophylline ) Concurrent use nephrotoxic drug Age less 18 Pregnancy Uncontrolled bacterial infection Renal parenchymal disease ( e.g . acute tubular necrosis , glomerular disease , interstitial nephritis urinary obstruction ) Shock TNF alpha antagonist use Subject institutionalize prisoner Recent cerebral retinal hemorrhage ( contraindication PTX ) Severe poorly control cardiovascular disease determine principal investigator hinder ability adhere study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatorenal syndrome</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Pentoxyfylline</keyword>
	<keyword>Liver transplantation</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>